| __timestamp | AstraZeneca PLC | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 3243000 |
| Thursday, January 1, 2015 | 4646000000 | 2472000 |
| Friday, January 1, 2016 | 4126000000 | 2548000 |
| Sunday, January 1, 2017 | 4318000000 | 19623000 |
| Monday, January 1, 2018 | 4936000000 | 30421000 |
| Tuesday, January 1, 2019 | 4921000000 | 32793999 |
| Wednesday, January 1, 2020 | 5299000000 | 28304000 |
| Friday, January 1, 2021 | 12437000000 | 620000 |
| Saturday, January 1, 2022 | 12391000000 | 755000 |
| Sunday, January 1, 2023 | 8040000000 | 1322000 |
| Monday, January 1, 2024 | 10207000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for AstraZeneca PLC and Viridian Therapeutics, Inc. from 2014 to 2023. AstraZeneca, a global leader, consistently reported higher costs, peaking in 2021 with a 98% increase from 2016. In contrast, Viridian's costs fluctuated, with a notable spike in 2019, reaching over 1,200% of its 2014 costs. By 2023, AstraZeneca's costs decreased by 35% from its 2021 peak, while Viridian's costs showed a significant reduction, dropping by 96% from 2019. This data highlights AstraZeneca's substantial scale and Viridian's dynamic cost management strategies. Understanding these trends offers valuable insights into the operational efficiencies of these pharmaceutical giants.
Cost Insights: Breaking Down AstraZeneca PLC and Takeda Pharmaceutical Company Limited's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Regeneron Pharmaceuticals, Inc.'s Expenses
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: AstraZeneca PLC and Galapagos NV
Analyzing Cost of Revenue: Pfizer Inc. and Viridian Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Analyzing Cost of Revenue: Evotec SE and Viridian Therapeutics, Inc.